Marex Group PLC (MRX) Q4 Results Surpass Expectations for Earnings and Revenue
Marex Group PLC Reports Strong Quarterly Results
Marex Group PLC (MRX) announced quarterly earnings of $1.12 per share, surpassing the Zacks Consensus Estimate of $1.02. This result also marks an increase from the $0.76 per share reported in the same period last year, with all figures adjusted for one-time items.
The company delivered a positive earnings surprise of 10.16% this quarter. In the previous quarter, Marex was projected to earn $0.92 per share but achieved $0.96, resulting in a 4.35% surprise. Notably, Marex has exceeded consensus EPS estimates in each of the past four quarters.
For the quarter ending December 2025, Marex generated $572.1 million in revenue, beating consensus expectations by 8.76% and improving from $415.6 million a year earlier. The company has consistently outperformed revenue estimates over the last year.
The immediate impact of these results on Marex’s share price will largely depend on insights shared by management during the earnings call and future earnings projections.
Since the start of the year, Marex shares have climbed approximately 14.2%, outpacing the S&P 500’s 0.5% gain.
What Lies Ahead for Marex Group PLC?
Although Marex Group PLC has delivered strong performance so far this year, investors are now considering the company’s future prospects.
One of the most reliable indicators for future stock performance is the company’s earnings outlook, which includes both current consensus estimates for upcoming quarters and recent changes to those estimates.
Research indicates that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools like the Zacks Rank, which has a proven record of leveraging earnings estimate trends.
Prior to this earnings announcement, analyst estimate revisions for Marex were mixed. Following the latest report, these revisions may shift, but currently, the stock holds a Zacks Rank #3 (Hold), suggesting its performance is likely to mirror the broader market in the near term.
Looking ahead, the consensus forecast for the next quarter is earnings of $1.08 per share on $529 million in revenue. For the current fiscal year, analysts expect $4.41 per share in earnings and $2.17 billion in revenue.
It’s important to remember that the overall industry outlook can also significantly influence Marex’s stock performance. The Financial - Miscellaneous Services sector, where Marex operates, currently ranks in the lower 44% of over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the bottom half by more than two to one.
Industry Peers: Qfin Holdings Inc. - Sponsored ADR
Another company in the same sector, Qfin Holdings Inc. - Sponsored ADR (QFIN), has yet to announce its results for the quarter ending December 2025. QFIN is anticipated to report earnings of $1.13 per share, reflecting a 37.9% decrease from the prior year. The consensus EPS estimate has remained steady over the past month.
QFIN’s revenue for the quarter is projected at $628.45 million, representing a 2.3% increase year-over-year.
Is Marex Group PLC (MRX) a Good Investment?
If you’re considering investing in Marex Group PLC (MRX), you may want to explore the top stock picks for the next month. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.
Since 1978, Zacks Investment Research has provided independent analysis and investment tools. Over more than 25 years, the Zacks Rank stock-rating system has achieved an average annual return of +24.08%, more than doubling the S&P 500 (from January 1, 1988 through May 6, 2024).
For the latest stock recommendations from Zacks Investment Research, you can download the 7 Best Stocks for the Next 30 Days.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why Resideo Technologies (REZI) Might be Well Poised for a Surge

Dover's DFS Boosts Portfolio With ProGauge LR120 Radar Launch
Theravance Biopharma Plummets As Phase 3 Study Falls Short
Wolverine's Brand Momentum Sets the Stage for Solid Growth in 2026
